Changcun Guo1, Christopher J Pirozzi, Giselle Y Lopez, Hai Yan. 1. The Preston Robert Tisch Brain Tumor Center at Duke, Pediatric Brain Tumor Foundation Institute, Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract
PURPOSE OF REVIEW: Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to α-ketoglutarate (α-KG) and reduce NADP to NADPH. Point mutations of IDH1 and IDH2 have been discovered in gliomas. IDH mutations cause loss of native enzymatic activities and confer novel activity of converting α-KG to 2-hydroxyglutarate (2-HG). The mechanisms of IDH mutations in gliomagenesis, and their value as diagnostic, prognostic marker and therapeutic target have been extensively studied. This review is to summarize the findings of these studies. RECENT FINDINGS: Crystal structural studies revealed conformation changes in mutant IDHs, which may explain the gain of function by mutant IDHs. The product of mutant IDHs, 2-HG, is an inhibitor of α-KG-dependent dioxygenases, which may cause genome-wide epigenetic changes in human gliomas. IDH mutations are a favorable prognostic factor for human glioma and can be used as biomarker for differential diagnosis and subclassification rather than predictor of response to treatment. Preliminary data suggested that inhibiting production of the substrate of mutant IDH enzymes caused slow-down of glioma cell growth. SUMMARY: As valuable diagnostic and prognostic markers of human gliomas, there is still a lack of knowledge on biological functions of mutant IDHs, making targeting IDHs in glioma both difficult and unsecured.
PURPOSE OF REVIEW: Isocitrate dehydrogenases, IDH1 and IDH2, decarboxylate isocitrate to α-ketoglutarate (α-KG) and reduce NADP to NADPH. Point mutations of IDH1 and IDH2 have been discovered in gliomas. IDH mutations cause loss of native enzymatic activities and confer novel activity of converting α-KG to 2-hydroxyglutarate (2-HG). The mechanisms of IDH mutations in gliomagenesis, and their value as diagnostic, prognostic marker and therapeutic target have been extensively studied. This review is to summarize the findings of these studies. RECENT FINDINGS: Crystal structural studies revealed conformation changes in mutant IDHs, which may explain the gain of function by mutant IDHs. The product of mutant IDHs, 2-HG, is an inhibitor of α-KG-dependent dioxygenases, which may cause genome-wide epigenetic changes in humangliomas. IDH mutations are a favorable prognostic factor for humanglioma and can be used as biomarker for differential diagnosis and subclassification rather than predictor of response to treatment. Preliminary data suggested that inhibiting production of the substrate of mutant IDH enzymes caused slow-down of glioma cell growth. SUMMARY: As valuable diagnostic and prognostic markers of humangliomas, there is still a lack of knowledge on biological functions of mutant IDHs, making targeting IDHs in glioma both difficult and unsecured.
Authors: Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Emiko J Holmes; Tianni Zhou; Regina I Jakacki Journal: Childs Nerv Syst Date: 2010-08-20 Impact factor: 1.475
Authors: Susan C Williams; Matthias A Karajannis; Luis Chiriboga; John G Golfinos; Andreas von Deimling; David Zagzag Journal: Acta Neuropathol Date: 2010-12-24 Impact factor: 17.088
Authors: Brock C Christensen; Ashley A Smith; Shichun Zheng; Devin C Koestler; E Andres Houseman; Carmen J Marsit; Joseph L Wiemels; Heather H Nelson; Margaret R Karagas; Margaret R Wrensch; Karl T Kelsey; John K Wiencke Journal: J Natl Cancer Inst Date: 2010-12-16 Impact factor: 13.506
Authors: Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu Journal: Science Date: 2006-09-07 Impact factor: 47.728
Authors: Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick Journal: Cancer Cell Date: 2010-12-09 Impact factor: 38.585
Authors: Sandra Camelo-Piragua; Michael Jansen; Aniruddha Ganguly; James ChulMin Kim; Arjola K Cosper; Dora Dias-Santagata; Catherine L Nutt; A John Iafrate; David N Louis Journal: J Neuropathol Exp Neurol Date: 2011-02 Impact factor: 3.148
Authors: Walter Taal; Hendrikus J Dubbink; Chris B L Zonnenberg; Bernard A Zonnenberg; Tjeerd J Postma; Johanna M M Gijtenbeek; Willem Boogerd; Floris H Groenendijk; Johan M Kros; Mathilde C M Kouwenhoven; Ronald van Marion; Irene van Heuvel; Bronno van der Holt; Jacoline E C Bromberg; Peter A E Sillevis Smitt; Winand N M Dinjens; Martin J van den Bent Journal: Neuro Oncol Date: 2010-12-21 Impact factor: 13.029
Authors: Alexander S Chen; Joanna Wardwell-Ozgo; Nilang N Shah; Deidre Wright; Christina L Appin; Krishanthan Vigneswaran; Daniel J Brat; Harley I Kornblum; Renee D Read Journal: Cancer Res Date: 2018-12-10 Impact factor: 12.701
Authors: Qian Zhao; James R Manning; James Sutton; Abran Costales; Martin Sendzik; Cynthia M Shafer; Julian R Levell; Gang Liu; Thomas Caferro; Young Shin Cho; Mark Palermo; Gregg Chenail; Julia Dooley; Brian Villalba; Ali Farsidjani; Jinyun Chen; Stephanie Dodd; Ty Gould; Guiqing Liang; Kelly Slocum; Minying Pu; Brant Firestone; Joseph Growney; Tycho Heimbach; Raymond Pagliarini Journal: ACS Med Chem Lett Date: 2018-06-11 Impact factor: 4.345
Authors: Charles Chesnelong; Myriam M Chaumeil; Michael D Blough; Mohammad Al-Najjar; Owen D Stechishin; Jennifer A Chan; Russell O Pieper; Sabrina M Ronen; Samuel Weiss; H Artee Luchman; J Gregory Cairncross Journal: Neuro Oncol Date: 2013-12-22 Impact factor: 12.300